144 related articles for article (PubMed ID: 37247475)
1. Barriers and facilitators of naloxone and safe injection facility interventions to reduce opioid drug-related deaths: A qualitative analysis.
Miller NM; Campbell C; Shorter GW
Int J Drug Policy; 2023 Jul; 117():104049. PubMed ID: 37247475
[TBL] [Abstract][Full Text] [Related]
2. "That's why we're speaking up today": exploring barriers to overdose fatality prevention in Indianapolis' Black community with semi-structured interviews.
Seo DC; Satterfield N; Alba-Lopez L; Lee SH; Crabtree C; Cochran N
Harm Reduct J; 2023 Oct; 20(1):159. PubMed ID: 37891632
[TBL] [Abstract][Full Text] [Related]
3. Why is it so hard to implement change? A qualitative examination of barriers and facilitators to distribution of naloxone for overdose prevention in a safety net environment.
Drainoni ML; Koppelman EA; Feldman JA; Walley AY; Mitchell PM; Ellison J; Bernstein E
BMC Res Notes; 2016 Oct; 9(1):465. PubMed ID: 27756427
[TBL] [Abstract][Full Text] [Related]
4. A qualitative examination of naloxone access in three states: Connecticut, Kentucky, and Wisconsin.
Spector AL; Galletly CL; Christenson EA; Montaque HDG; Dickson-Gomez J
BMC Public Health; 2022 Jul; 22(1):1387. PubMed ID: 35854278
[TBL] [Abstract][Full Text] [Related]
5. Providers' perceptions on barriers and facilitators to prescribing naloxone for patients at risk for opioid overdose after implementation of a national academic detailing program: A qualitative assessment.
Bounthavong M; Suh K; Christopher MLD; Veenstra DL; Basu A; Devine EB
Res Social Adm Pharm; 2020 Aug; 16(8):1033-1040. PubMed ID: 31706950
[TBL] [Abstract][Full Text] [Related]
6. Stigma by Association: To what Extent is the Attitude Toward Naloxone Affected by the Stigma of Opioid Use Disorder?
Adeosun SO
J Pharm Pract; 2023 Aug; 36(4):941-952. PubMed ID: 35505618
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of the distribution of take-home naloxone in low- and middle-income countries and barriers to the implementation of take-home naloxone programs.
Sajwani HS; Williams AV
Harm Reduct J; 2022 Oct; 19(1):117. PubMed ID: 36266701
[TBL] [Abstract][Full Text] [Related]
8. "They're not doing enough.": women's experiences with opioids and naloxone in Toronto.
Macleod ER; Tajbakhsh I; Hamilton-Wright S; Laliberte N; Wiese JL; Matheson FI
Subst Abuse Treat Prev Policy; 2021 Mar; 16(1):26. PubMed ID: 33743756
[TBL] [Abstract][Full Text] [Related]
9. If we build it, will they come? Perspectives on pharmacy-based naloxone among family and friends of people who use opioids: a mixed methods study.
Slocum S; Ozga JE; Joyce R; Walley AY; Pollini RA
BMC Public Health; 2022 Apr; 22(1):735. PubMed ID: 35418048
[TBL] [Abstract][Full Text] [Related]
10. Addiction stigma and the production of impediments to take-home naloxone uptake.
Fomiatti R; Farrugia A; Fraser S; Dwyer R; Neale J; Strang J
Health (London); 2022 Mar; 26(2):139-161. PubMed ID: 32529843
[TBL] [Abstract][Full Text] [Related]
11. Why aren't Australian pharmacists supplying naloxone? Findings from a qualitative study.
Olsen A; Lawton B; Dwyer R; Taing MW; Chun KLJ; Hollingworth S; Nielsen S
Int J Drug Policy; 2019 Jul; 69():46-52. PubMed ID: 31078908
[TBL] [Abstract][Full Text] [Related]
12. Personal experience and awareness of opioid overdose occurrence among peers and willingness to administer naloxone in South Africa: findings from a three-city pilot survey of homeless people who use drugs.
Wilson M; Brumwell A; Stowe MJ; Shelly S; Scheibe A
Harm Reduct J; 2022 Feb; 19(1):17. PubMed ID: 35148779
[TBL] [Abstract][Full Text] [Related]
13. How do naloxone-based interventions work to reduce overdose deaths: a realist review.
Miller NM; Waterhouse-Bradley B; Campbell C; Shorter GW
Harm Reduct J; 2022 Feb; 19(1):18. PubMed ID: 35197057
[TBL] [Abstract][Full Text] [Related]
14. Barriers to implementation of opioid overdose prevention programs in Ohio.
Winstanley EL; Clark A; Feinberg J; Wilder CM
Subst Abus; 2016; 37(1):42-6. PubMed ID: 26682929
[TBL] [Abstract][Full Text] [Related]
15. How prepared are pharmacists to provide over-the-counter naloxone? The role of previous education and new training opportunities.
Lai Joyce Chun K; Olsen A; Taing MW; Clavarino A; Hollingworth S; Dwyer R; Middleton M; Nielsen S
Res Social Adm Pharm; 2019 Aug; 15(8):1014-1020. PubMed ID: 30926251
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the impact of naloxone dispensation at public health vending machines in Clark County, Nevada.
Allen ST; O'Rourke A; Johnson JA; Cheatom C; Zhang Y; Delise B; Watkins K; Reich K; Reich R; Lockett C
Ann Med; 2022 Dec; 54(1):2692-2700. PubMed ID: 36168975
[TBL] [Abstract][Full Text] [Related]
17. Legacies of the war on drugs: Next of kin of persons who died of opioid overdose and harm reduction interventions in Philadelphia.
Uzwiak BA; Hudgins A; Pizzicato LN
Int J Drug Policy; 2021 Nov; 97():103351. PubMed ID: 34252788
[TBL] [Abstract][Full Text] [Related]
18. Neighborhood-Level and Spatial Characteristics Associated with Lay Naloxone Reversal Events and Opioid Overdose Deaths.
Rowe C; Santos GM; Vittinghoff E; Wheeler E; Davidson P; Coffin PO
J Urban Health; 2016 Feb; 93(1):117-30. PubMed ID: 26800987
[TBL] [Abstract][Full Text] [Related]
19. Community-based opioid overdose prevention programs providing naloxone - United States, 2010.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2012 Feb; 61(6):101-5. PubMed ID: 22337174
[TBL] [Abstract][Full Text] [Related]
20. Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose.
Donovan E; Case P; Bratberg JP; Baird J; Burstein D; Walley AY; Green TC
J Urban Health; 2019 Jun; 96(3):367-378. PubMed ID: 30747371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
